[Improvement of total prostate specific antigen(PSA) assay from the "Skewed molar-response" to the "Equimolar-response" by utilizing anti free-PSA monoclonal antibodies].
Prostate specific antigen(PSA) is widely used as a marker for screening and monitoring prostate cancer. However, there are several assay methods, which often give different PSA values for the same patient sample. A possible cause of these discrepancies might be the varied immunoreactivity with free-PSA and complex-PSA among methods. This study revealed that pre-treatment of samples with anti-free-PSA monoclonal antibodies improved polyclonal antibodies-based non equimolar PSA assay to equimolar assay. This might be achieved by that the monoclonal antibodies bind to free-PSA and then change its reactivities with polyclonal antibodies to those similar to complex-PSA.
Kimura
Emi
E
Japan Clinical Laboratories, Inc., Kuze-gun, Kyoto-pref. 613-0046.
Matsumoto
Kyoichi
K
Samori
Tomohiro
T
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000276:immunology
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen